![](/sites/all/themes/mda_bootstrap_subtheme/img/ico-category-research.png)
Medical Educational Resource
The CIFFREO Study
Activity Snapshot
This Industry Update Webinar is sponsored by Pfizer. This program is not sponsored, endorsed, or accredited by MDA.
Faculty
![](https://www.mda.org/sites/default/files/styles/med_ed_faculty/public/default_images/default-faculty.png?itok=nyX_B0dM)
Duchenne Muscular Dystrophy Gene Therapy Program Pfizer
This Industry Update Webinar for clinicians is presented by Pfizer and features information on the CIFFREO study. On June 15, 2022 at 12:00PM EST in a 30-minutes webinar, Dr. Kasia Labello, Global Clinical Lead for the Duchenne Muscular Dystrophy Gene Therapy Program at Pfizer, provided an overview of the CIFFREO study. The CIFFREO Study is a Phase 3, Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of mini-dystrophin Gene Therapy (fordadistrogene movaparvovec) in Ambulatory Boys with DMD.